Turnstone Biologics Corp. (TSBX) Stock Statistics & Valuation Metrics

Turnstone Biologics Corp. has a market cap or net worth of $7.87M. The enterprise value is -$16.39M.

Turnstone Biologics Corp. has 23,138,897 shares outstanding. The number of shares has decreased by -2.65% in one year.

Turnstone Biologics Corp.’s return on equity (ROE) is -0.56 and return on invested capital (ROIC) is -57.09%.

The current PE Ratio of Turnstone Biologics Corp. is -0.53. Turnstone Biologics Corp.’s PEG ratio is >-0.01.

In the last 12 months, Turnstone Biologics Corp. had revenue of 19.31M and earned -55.20M in profits. Earnings per share was -4.77.

In the last 12 months, operating cash flow was -66.47M and capital expenditures -248.00K, giving a free cash flow of -66.71M billion.

Turnstone Biologics Corp. pays an annual dividend of ―, resulting in a dividend yield of ―

Turnstone Biologics Corp. upcoming earnings date is May 19, 2025, TBA Not Confirmed.

Turnstone Biologics Corp. as a current ratio of 8.57, with Debt / Equity ratio of 3.89%

In the past 12 months, Turnstone Biologics Corp. has paid -286.00K in taxes.

Turnstone Biologics Corp. EV to EBITDA ratio is -0.26, with an EV/FCF ratio of -0.22.

Turnstone Biologics Corp. has $45.28M in cash and marketable securities with $5.17M in debt, giving a net cash position of -$43.59M billion.

Gross margin is 0.00%, with operating margin of -305.77%, and net profit margin of -285.92%.

The average price target for Turnstone Biologics Corp. is $1.00, which is 11.43% higher than the current price. The consensus rating is Hold